Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the quarter and year ended March 31, 2026.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts less than Nifty Smallcap 250 and 5.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure Limited reported FY2026 standalone revenue of Rs 4,448.44 lakhs with net profit after tax of Rs 3,359.85 lakhs, marginally higher than Rs 3,313.35 lakhs in FY2025. On a consolidated basis, revenue grew significantly to Rs 5,522.68 lakhs (up 21.2% from Rs 4,651.38 lakhs) driven by acquisitions of Pendracare Group and Medstream SA (Citieffe Group). However, consolidated net profit declined to Rs 3,207.30 lakhs from Rs 3,385.57 lakhs in the prior year. The Board recommended a dividend of Rs 3.5 per share (70% payout). An exceptional item of Rs 680.40 lakhs was recorded due to the impact of new Labour Codes. Statutory auditors issued unmodified audit opinions on both standalone and consolidated financial results.
The company delivered strong consolidated revenue growth from acquisitions, but profitability declined on a consolidated basis due to acquisition-related costs and integration expenses. The dividend payout signals management confidence, though shareholders should monitor margin recovery in coming quarters.